MedPath

evofloxacin effect on eradication of Helicobacter Pylori infectio

Phase 3
Conditions
Helicobacter Pylori infection.
Helicobacter pylori
Registration Number
IRCT2015081818124N2
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

Inclusion criteria to this study: all patients undergoing upper endoscopic procedure with positive rapid urease test (RUT). Exclusion criteria from this study: pregnancy; Previous consumption proton pump inhibitors (PPI) or Bismuth in the preceding one month; Gastrointestinal (GI) bleeding or any complication of peptic ulcer disease (PUD); consumption of alcohol or substance; advanced chronic disease: Diabetes mellitus, Hypertension, Cirrhosis, Cerebrovascular attack, Renal insufficiency, Coronary artery disease and gastric cancer; lack of willingness to continue the treatment; lack of willingness to complete the period of treatment; suffering from any disease needing to consume another antibiotic or non-steroidal anti-inflammatory drugs (NSAIDs).

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Eradication of Helicobacter Pylori infection. Timepoint: Two months after beginning of treatment. Method of measurement: Primary evaluation of Helicobacter Pylori infection is based on rapid urease test and then eradication will be assessed by Helicobacter Pylori stool antigen.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath